Investors Urged to Join Soleno Therapeutics, Inc. Securities Fraud Class Action Suit by Rosen Law Firm

Opportunity for Investors in Soleno Therapeutics

In a significant development for investors, the Rosen Law Firm has announced a reminder for those who purchased common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) during a specified class period. The firm is encouraging participation in a pending securities fraud lawsuit that has the potential to offer compensation to affected investors at no upfront cost.

Important Deadline for Investors

The Rosen Law Firm has set a crucial deadline for potential lead plaintiffs, which is May 5, 2026. Any investor who bought shares between March 26, 2025, and November 4, 2025, may qualify to take part in this legal action. To join the class action, interested parties are urged to visit the firm's website or contact them directly. The law firm operates on a contingency fee basis, meaning that investors won’t have to pay any costs upfront.

Class Action Details

The lawsuit stems from allegations that Soleno Therapeutics made false or misleading statements regarding its clinical trial program for a drug called diazoxide choline extended-release tablets (DCCR). The complaints highlight that the safety concerns associated with DCCR were systematically downplayed or concealed, particularly regarding its use in treating hyperphagia in patients with Prader-Willi syndrome.

Key points raised in the lawsuit include:

1. Underreporting of Risks: The clinical trials did not adequately disclose significant safety concerns about the drug, such as excessive fluid retention in participants.
2. Misleading Information: Investors were led to believe that DCCR posed fewer risks than what was later revealed, which could impact its commercial viability.
3. Consequences Post-Market Entry: Once the truth surfaced, investors allegedly faced financial losses due to decreased market confidence and potential adverse regulatory actions against the drug.

As the case progresses, investors are cautioned that no class has yet been certified. Until certification, individuals must select their counsel or act as absent class members, and their ability to recover in any potential future settlement will not depend on serving as lead plaintiff.

Why Choose Rosen Law Firm?

Rosen Law Firm emphasizes the importance of selecting qualified legal counsel, particularly firms with a strong track record in securities class actions. They highlight their impressive history of successful settlements, including a considerable amount recovered for investors in recent years. Their founding partner has been recognized for excellence in the field, underscoring their capability to effectively represent investor interests.

For those interested in pursuing this opportunity, further information can be obtained by visiting the firm’s homepage or reaching out via their toll-free number. The spokesperson for this class action is Phillip Kim, Esq., who can provide detailed insights about the process.

Conclusion

In summary, the ongoing class action lawsuit against Soleno Therapeutics offers affected investors an opportunity to seek restitution for their losses. The support of a reputable law firm can be pivotal in navigating these challenging legal waters, and interested parties should act promptly to ensure their eligibility before the critical deadline. Keep an eye on updates from the Rosen Law Firm through their social media platforms for the latest developments in this case.